Drug Trial Radar · NCT02980692
Efficacy and Safety Study of SUNPG1623
Last checked: Nov 20, 2026Latest source record: Jan 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
391
Actual
Start
Apr 19, 2017
Primary completion
Mar 1, 2019
Study completion Sep 24, 2019
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Conditions
- Active Psoriatic Arthritis
Interventions
SUNPG1623 IDrug
injection
SUNPG1623 IIDrug
injection
SUNPG1623 IIIDrug
injection
SUNPG1623 IVDrug
injection
PLACEBODrug
injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Who Achieve American College of Rheumatology20 Response RateTime frame: week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SPARC Site 1
Middleburg Heights, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.